Lercanidipin Ratiopharm

Lercanidipine Hydrochloride, the active ingredient in Lercanidipin Ratiopharm, is a calcium channel blocker presented as an oral tablet for systemic use. It belongs to the dihydropyridine subclass and is indicated for the management of hypertension in adult patients, helping to achieve target blood pressure levels.

GNH USA supplies Lercanidipin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to EU‑approved antihypertensive medicines. The company adheres to stringent quality standards and offers comprehensive logistics support for global distribution.

Lercanidipine is a calcium channel blocker used to treat conditions related to elevated blood pressure. - Hypertension: lowers systolic and diastolic blood pressure to achieve target levels. - Essential hypertension: provides sustained blood pressure control in patients with primary hypertension. - Isolated systolic hypertension: improves arterial compliance and reduces systolic pressure in older adults.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache often occurring after initiation. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Cardiac arrhythmia: irregular heart rhythm requiring medical evaluation. - Hepatic dysfunction: abnormal liver enzyme levels indicating possible liver injury.

When prescribing Lercanidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Cardiovascular status: assess for heart failure or recent myocardial infarction before initiation. - Liver function: evaluate hepatic enzymes in patients with known liver disease. - Concomitant vasodilators: use caution when combined with other blood pressure‑lowering agents. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Lercanidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Grapefruit juice: can markedly raise drug levels leading to enhanced adverse effects.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure reduction. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Simvastatin: increased risk of statin‑related muscle toxicity.